Mabwell (Shanghai) Bioscience Co., Ltd.SSE: 688062

(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Voluntary Disclosure of the Oral Presentation of Clinical Data for 9MW2821 at the 2026 European Society for Medical Oncology (ESMO) Congress

· Issued by Mabwell (Shanghai) Bioscience Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688062 · · 2 pages · Chinese

Summary by 6ix AI

The announcement includes details about the drug's clinical research data, specifically for patients with triple-negative breast cancer. The company emphasizes the potential risks associated with the drug's clinical trials and the uncertainty regarding its market approval.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688062mabwell-shanghai-bioscience-co-ltdannouncement-on-voluntary-disclosure-of-the-oral-presentation-of-clinical-data-for-9mw2821-at-the-2026-european-society-for-medical-oncology-esmo-congress

Release

Announcement on Voluntary Disclosure of the Oral Presentation of Clinical Data for 9MW2821 at the 2026 European Society for Medical Oncology (ESMO) Congress

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Mabwell (Shanghai) Bioscience Co., Ltd. on 6ix

Story so far

Earlier from Mabwell (Shanghai) Bioscience

All Mabwell (Shanghai) Bioscience news releases